When monitoring patients in whom PCa is suspected and with a cut-off point of ≥0.3–0.5 ng/mL/year, the specificity of the test became 90% with PSAV, compared with 60% if only total PSA were used. This evidence concerns the gene KLK3 and posterior cortical atrophy.